Climb Bio (CLYM) Stock Price, News & Analysis

Company Overview

Climb Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of targeted protein degraders for the treatment of cancer and other serious diseases. The company is leveraging an integrated drug discovery platform that combines medicinal chemistry, structural biology and proprietary assays to identify small molecules capable of directing disease-causing proteins to the cell’s natural degradation machinery. With a primary emphasis on oncology, Climb Bio’s lead programs are designed to address high-unmet-need targets that have historically proven difficult to modulate with traditional small-molecule inhibitors or biologics.

Since its formation as an independent public company, Climb Bio has built a pipeline that spans multiple therapeutic modalities and target classes. Its research and development efforts are supported by state-of-the-art laboratories in the United States, where multidisciplinary teams work on early-stage discovery as well as translational research. The company has also established strategic partnerships to broaden its scientific capabilities and expedite the advancement of its most promising candidates toward clinical evaluation. Through these collaborations, Climb Bio aims to capitalize on external expertise while retaining core control over its proprietary chemistry and screening platforms.

Climb Bio was founded by a group of industry veterans and academic scientists with deep experience in drug discovery, structural biology and oncology. The senior management team includes executives who have previously led successful biotech ventures and overseen late-stage clinical programs. Based in the U.S., with outreach to select research centers in Europe and Asia, the company combines global scientific collaboration with a nimble organizational structure. This approach is intended to streamline decision-making and foster rapid progress from target discovery through clinical development.

Key Stats

• Today's Range: $1.21 to $1.31
• 50-Day Range: $1.17 to $1.39
• 52-Week Range: $1.05 to $9.21
• Volume: 262,575 shs
• Average Volume: 353,630 shs
• Market Capitalization: $85.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Buy

Climb Bio Stock Analysis - MarketRank™

Climb Bio scored higher than 53% of companies evaluated by MarketBeat, and ranked 496th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Climb Bio has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Climb Bio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Climb Bio are expected to grow in the coming year, from ($1.57) to ($0.66) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Climb Bio is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Climb Bio is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Climb Bio has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CLYM.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Climb Bio does not currently pay a dividend.

Dividend Growth

Climb Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for CLYM.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for CLYM on MarketBeat in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Climb Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,540.00 in company stock.

Percentage Held by Insiders

Only 3.20% of the stock of Climb Bio is held by insiders.

Percentage Held by Institutions

69.76% of the stock of Climb Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CLYM Stock Analysis - Frequently Asked Questions

How have CLYM shares performed this year?

Climb Bio's stock was trading at $1.80 at the start of the year. Since then, CLYM shares have decreased by 30.0% and is now trading at $1.26.

How were Climb Bio's earnings last quarter?

Climb Bio, Inc. (NASDAQ:CLYM) posted its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.16.

How do I buy shares of Climb Bio?

Shares of CLYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CLYM
• Previous Symbol: NASDAQ:CLYM
• CIK: 1768446
• Web: climbbio.com
• Phone: 866-857-2596
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Climb Bio: $9.00
• High Price Target: $10.00
• Low Price Target: $7.00
• Potential Upside/Downside: +614.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$73.90 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -43.95%
• Return on Assets: -42.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.25
• Quick Ratio: 14.25

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.15 per share
• Price / Book: 0.40

Miscellaneous

• Outstanding Shares: 67,580,000
• Free Float: 65,414,000
• Market Cap: $85.15 million
• Optionable: N/A
• Beta: -0.13